AxoGen, Inc.
AXGN Healthcare Medical Devices
AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 23.1%, EPS fell 400.0%, free cash flow fell 17.4% and total debt fell 72.6%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow AXGN
AxoGen, Inc. (AXGN) EV/Sales
As of 16 October 2026, AxoGen, Inc. (AXGN) trades at a EV/Sales of 7.0×. Over the past ten years it has ranged from 1.2× (November 2023) to 27.6× (June 2018); the current reading is higher than 71% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.8× | 67.70% |
| FY2024 | 4.0× | 96.24% |
| FY2023 | 2.1× | (33.21%) |
| FY2022 | 3.1× | 8.31% |
| FY2021 | 2.9× | (51.34%) |
| FY2020 | 5.9× | 3.79% |
| FY2019 | 5.6× | (25.46%) |
| FY2018 | 7.6× | (50.21%) |
| FY2017 | 15.2× | 133.81% |
| FY2016 | 6.5× | 37.71% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 9.4× | 38.18% |
| Mar 2026 | 6.8× | 0.58% |
| Dec 2025 | 6.8× | 70.07% |
| Sep 2025 | 4.0× | 52.59% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| INSP Inspire Medical Systems, Inc. compare | 1.9× |
| NVCR NovoCure Limited compare | 2.0× |
| ATEC Alphatec Holdings, Inc. compare | 2.6× |
| NEOG Neogen Corporation compare | 3.6× |
| UFPT UFP Technologies, Inc. compare | 3.8× |
| TMDX TransMedics Group, Inc. compare | 4.2× |
| AXGN AxoGen, Inc. | 7.0× |
| ESTA Establishment Labs Holdings Inc. compare | 8.1× |
| BFLY Butterfly Network, Inc. compare | 16.3× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)